Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the ...
Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system. This is an ASCO Meeting Abstract ...
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts ...
In this multi-center, Phase-1 study (NCT03733717), we characterized the pharmacokinetics (PK) of the anti-CD38 antibody isatuximab (Isa) after IV administration (primary objective), and evaluated ...
Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries ...
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the ...
Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...
Preclinical studies have indicated that the combination of mTORC1/2 inhibitors with PD-1 antibodies exhibits synergistic effects on solid tumors. However, no clinical data supporting this combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results